Showing 127–132 of 229 results
English Name: Fulvestrant
Alias: (7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
Product Name: Fulvestrant
Molecular Structure: CAS Registry Number: 129453-61-8, Fulvestrant
Molecular Formula: C32H47F5O3S
Molecular Weight: 606.77
CAS Registry Number: 129453-61-8
关键字： 129453-61-8;氟维司群;
Product Name: Hydrobromide Galantamine; 11-Methyl-3-methoxy-4a,5,9,10,11,12-hexahydro-6H-benzo[b]furan[3a,3,2ef][2]benzazepine-6-ol hydrobromide
Molecular Structure: CAS Registry Number: 1953-04-4, Hydrobromide Galantamine, 11-Methyl-3-methoxy-4a,5,9,10,11,12-hexahydro-6H-benzo[b]furan[3a,3,2ef][2]benzazepine-6-ol hydrobromide
Molecular Formula: C17H21NO3·HBr; C17H22BrNO3
Molecular Weight: 368.27
CAS Registry Number: 1953-04-4
EC Number: 217-780-5
English Name: Gamithromycin
Alias: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-Cmethyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one
Product Name: Gamithromycin
Molecular Structure: CAS Registry Number: 145435-72-9, Gamithromycin
Molecular Formula: C40H76N2O12
Molecular Weight: 777.04
CAS Registry Number: 145435-72-9
EC Number: 604-472-4
关键字： 145435-72-9;Gamithromycin;加米霉素;
Chinese Name: GANT61
English Name: GANT61
CAS: 500579-04-4
Product Category: Intermediate
English Name: 2,2'-[[Dihydro-2-(4-pyridinyl)-1,3(2H,4H)-pyrimidinediyl]bis(methylene)]bis[N,N-dimethylbenzenamine]; GANT61
Product Name: 2,2'-[[二氢-2-(4-吡啶基)-1,3(2H,4H)-嘧啶二基]二(亚甲基)]二[N,N-二甲基苯胺]
Molecular Formula: C₂₇H₃₅N₅
Molecular Weight: 429.60
CAS Registration Number: 500579-04-4
Keywords: 500579-04-4; GANT61; GLI1 and GLI2 inhibitors
Appearance: White crystalline powder.
Product Name: Ibrutinib
Brand Name: Imbruvica
CAS No.: 936563-96-1
Purity: ≥99.0%
Category: API (Active Pharmaceutical Ingredient)
Shelf Life: 1 year
Storage: Room temperature, protect from light
Manufacturer: Janssen (USA)
Description:
Ibrutinib is a novel kinase inhibitor approved by the FDA for the treatment of:
Mantle Cell Lymphoma (MCL) in patients who have received at least one prior therapy
Chronic Lymphocytic Leukemia (CLL) in previously treated patients
Note: Generally well-tolerated, but long-term use may lead to adverse effects such as nail and hair abnormalities.
Keywords: 936563-96-1; Ibrutinib; Imbruvica; Ibrutinib Capsules